Business Wire

THERAMEX

15.11.2021 11:02:05 CET | Business Wire | Press release

Share
Theramex Enters OTC Market with Femarelle®, a Non-hormonal Option to Treat Menopause Symptoms

Theramex, a company dedicated women’s health, recently acquired the Femarelle® product licence to treat menopause symptoms. Femarelle will be available in different markets from the 2nd quarter of 2022. This commercialisation agreement was reached with Se-cure Pharmaceuticals Ltd., the company that developed the product.

Femarelle® offers non-hormonal therapy to balance oestrogen levels in women from peri-menopause through menopause to post-menopause relieving the symptoms and conditions derived from oestrogen loss with the onset of menopause. It addresses specific needs at each menopause stage and is characterised by the natural compound DT56a, an oestrogen receptor modulator, supplemented with stage-appropriate vitamins and minerals. DT56a is developed from the soybean plant taking advantage of the 20 amino acids of soybean in its production process, resulting in a unique compound targeting the oestrogen receptors in the woman's body:

  • Femarelle® Rejuvenate, for women over 40 experiencing menstrual cycle fluctuations, the telltale sign of the onset of perimenopause. Femarelle Rejuvenate restores a woman's hormonal balance, supporting changing moods, loss of skin elasticity and fatigue.
  • Femarelle® Recharge, for women over 50 who may already be feeling classic menopause symptoms such as hot flushes and night sweats and which assists with additional aspects of menopause such as loss of libido.
  • Femarelle ®Unstoppable, for women over 60 who have gone through the bulk of their menopause and are now focused on maintaining bone and vaginal health as they age.

The DT56a compound adheres to oestrogen receptors without being recognised as oestrogen by the body. This unique non-hormonal botanical solution was declared a “first-line treatment for menopause management” at the Presidential Conference of the Annual Congress of the European Society of Gynaecology in 2017. Femarelle® is supported by gynaecologists around the world and has been published in leading journals.

In a survey of 4,000-plus women from different countries, hot flushes and night sweats were the main symptoms in all countries. Femarelle® was found to significantly relieve menopausal symptoms within the first two weeks of treatment and this trend continued following four weeks of treatment in all the countries surveyed. A statistically significant reduction was found at each week of treatment1 .

With this move, Theramex steps up its commitment to provide women with an effective and safe alternative to menopause hormone therapy. “Our main objective is to meet women’s health needs around the world,” said Theramex chief executive Robert Stewart . “Not only their current needs but future ones too in order to improve their lives. With Femarelle®, we are adding to our portfolio an alternative for women with untreated menopause who are reluctant to use hormone therapy”.

Esti Grunbaum , Vice President BD & Marketing at Se-cure Pharmaceuticals Ltd., said: “We are very excited about this collaboration with Theramex. Together we will provide women with more menopausal symptom treatment options”.

Jose Naranjo , Theramex Vice President Marketing, said: “We offer a non-hormonal option to healthcare professionals, backed by scientific studies verifying its safety and efficacy. This allows us to cover an unmet need for these women who will now be heard, understood and have access to a treatment that will provide them with greater adherence and therefore a better quality of life”.

About Theramex

Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.

About Se-cure Pharmaceuticals Ltd.

Se-cure Pharmaceuticals Ltd. is a research-driven biotech company focused on the discovery and development of therapeutic solutions originating from botanical sources with an emphasis on safety of use. Founded in 1997, Se-cure’s competencies include target-manipulated germination and proprietary agro-technologies used to engineer botanicals into tissue-targeted therapeutics.

Se-cure develops unique botanical therapies that integrate the pharmaceutical world with the supplement world, balancing them both to create highly effective therapies that can be taken for the long-term, improving quality of life without incurring risks. The API in our products are developed in-house, providing proprietary products with vast scientific support.

Se-cure has a state-of-the-art biotech-pharmaceutical manufacturing facility operating under rigorous quality control standards, producing standardised nutraceuticals with swift efficacy and the highest safety. We are dedicated to bringing forth unique botanical therapies that provide proven relief of symptoms while avoiding the risks of the conventional options

1 Genazzani A., Nachtigall L., Panay N. & Yoles I. Symposium: 2 Continents, 3 cultures, 4 countries, 2,000 women and Femarelle®; 13th World Congress on Menopause . Rome, Italy June 2011.
Sánchez-Borrego R., Mendoza N., Llaneza P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms; Climacteric . 2015;18(6):813-6.
Chen F.P et al. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. Taiwan J Obstet Gynecol . 2016;55(3):336-40.

THX_HQ_PRESSR_006034

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release

With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors

Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release

The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re

Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release

Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr

Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press release

Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa

UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release

Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye